about
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseWhere Failure Is Not an Option -Personalized Medicine in AstronautsSimultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Therapeutic drug monitoring of non-tricyclic antidepressant drugs.Pharmacogenomics and antidepressant drugs.Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family.Lithium and venlafaxine interaction: a case of serotonin syndrome.Implementation of CYP2D6 genotyping in psychiatry.Pharmacogenetic considerations in the treatment of psychiatric disorders.Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs.Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.PharmGKB summary: venlafaxine pathway.Clinical applications of CYP genotyping in psychiatry.Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder.Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue.Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study.Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspectsHigh-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency
P2860
Q24683013-5301136D-DE46-4D78-90E5-4C97E25A3264Q28252209-EDF2745A-5CCF-40A1-9C64-668A03AB64DAQ28550427-CCE8CCD8-9A42-4C77-84EE-8604BC675BE3Q33942956-03C00B37-AD30-4D74-8CF0-4E93F071F858Q34273354-FEA95E84-8248-45F9-82CE-3B6E30AD18B5Q34453981-E9308959-8983-4DA0-8272-6D7825C73B7CQ34473840-D72635D2-06A3-4B21-8CE6-BB691F967657Q34564302-B2D73265-8C8A-40E7-8D58-2436E59A4F32Q35236618-4928DBAE-4EF3-469F-8B74-46B593D5DEBCQ35970340-5473A970-B0F3-43E5-8A98-963951894236Q36438205-F767AE82-2441-4669-9E00-C6CBC4F5E168Q36441503-12FC35C5-A68F-4008-AD1D-70F7D3844EA7Q36553798-CD2EB0D5-6823-433B-902B-CB5BCB1C63DAQ37538787-56470154-ECAA-4B69-91AF-0ED2E5453733Q37681573-519456AA-0AFE-485A-98D1-2D37EE180D67Q37826340-4D83241A-BE7A-47CA-985D-884C1A784FE0Q37989490-22EA110E-52E1-4E48-8BA0-C5EEFB845024Q38152886-BAE54EE5-2C54-4E26-9FCA-E2D25FC0E811Q38247063-8A36FD97-FD00-4262-9B6A-8853B1254A2DQ39025173-9A1A0FF5-F1FB-4375-A939-AF88E112034DQ39441964-31C51A57-EDFD-431D-97B2-D78551BC8B77Q44263557-EA3FACA7-7C79-4E3D-95E1-005D9A64499BQ45176540-030DA90D-B7EE-4110-8B91-3D313C3D8A75Q46850739-1365AA64-B4F2-402D-8E35-ABEB2BBEB3EFQ47151234-09D5ABC1-6B26-4127-92A2-47949318CCA9Q47894175-93900319-FEFD-437A-AB41-D5ED258DF50FQ48356516-686EDC7F-EC48-481C-9474-FA120930E662Q49670994-6B082ED4-5E2A-469B-9EAF-41AD6CCF327FQ50449208-25DDCD05-D613-474E-991C-CC8417005749Q57550294-F867684B-815F-48F4-BAC9-50A460F222A1Q57550310-3786A42C-89A7-48BB-862C-18145D3F0F0A
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Venlafaxine serum levels and CYP2D6 genotype
@ast
Venlafaxine serum levels and CYP2D6 genotype
@en
Venlafaxine serum levels and CYP2D6 genotype
@nl
type
label
Venlafaxine serum levels and CYP2D6 genotype
@ast
Venlafaxine serum levels and CYP2D6 genotype
@en
Venlafaxine serum levels and CYP2D6 genotype
@nl
prefLabel
Venlafaxine serum levels and CYP2D6 genotype
@ast
Venlafaxine serum levels and CYP2D6 genotype
@en
Venlafaxine serum levels and CYP2D6 genotype
@nl
P2093
P1476
Venlafaxine serum levels and CYP2D6 genotype
@en
P2093
A H Veefkind
E Hoencamp
P M Haffmans
P356
10.1097/00007691-200004000-00011
P407
P577
2000-04-01T00:00:00Z